Qilian International Corp - QLI Net Assets per Single Share

Public company logo of qlsyy.net (QLI)

Qilian International (QLI) operates based on the production of antibiotics and traditional remedies, creating a heavy dependence on Chinese regulations. Revenue is generated by veterinary drugs, licorice extracts, and pharmacy sales. This book value per share chart visualizes the capital accumulation vector, where 1.19 characterizes this valuation parameter. Primary threats remain environmental fines, geopolitics, and the unpredictability of the PRC regulator.

Accounting Value of a Share: Qilian International Holding Group (QLI) for 07/04/2022 - 08/17/2024

qlsyy.net - analytical breakdowns and key metrics (QLI)

- price and consensus price forecast:
Stock Price Qilian International Holding Group Limited|QLI - Analyst Median Target
- market capitalization data:
Market Value Qilian International Holding|QLI - Full Business Value
- book capitalization data:
Book Value per Share Qilian International|QLI - Accounting Value of Company|Market Capitalization to Book Value Ratio qlsyy.net|QLI - Company Total Assets
- debt and liquidity data:
Debt to Equity Qilian International|QLI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Qilian International Holding|QLI - Company Total Debt|Debts to Book Capitalization Qilian International Holding
Analysis of all company metrics:Qilian International Holding Group Limited (QLI)
Signature product of Qilian International Holding

Analyzing the historical book value per share of Qilian International (QLI), one can confirm the resilience of the Chinese pharmaceutical and agrochemical manufacturer through asset diversification. This metric reflects the net capital value per share, adjusting under the influence of earnings or share buybacks, which allows an investor to assess the company's internal fundamentals and the protection of investments against market volatility.

Competitor analysis

Book Value per Share HLN (Haleon Group)|KVUE: Net Assets per Share|Net Assets per Single Share Verona Pharma plc (VRNA)|jyongbio.com (MENS) - Share Book Value|LGND - Book Value per Share|Accounting Value of a Share Amneal Pharmaceuticals, Inc.|Book Value per Share PRGO|Book Value per Share ALVO (Alvotech Biopharmaceuticals)|Net Assets per Single Share Liquidia Corporation|glpg.com - Accounting Value of a Share|ANIP: Net Assets per Single Share|MNKD - Accounting Value per Share|AMPH: Book Value per Share|Book Value per Share Pacira Corp|SPRY - Accounting Value per Share|Accounting Value of a Share TBPH|Aquestive Therapeutics, Inc. - Net Assets per Single Share|Net Asset Value per Share scpharmaceuticals.com SCPH|Accounting Value per Share Tectonic Therapeutic (TECX)|Book Price of a Share Tonix Pharmaceuticals Holding TNXP|Book Value per Share SXT China (SXTC)|EPRX - Accounting Value of a Share|Book Value per Share BHST|EXOZ (Invizyne Technologies) - Net Asset Value per Share|ORMP - Net Assets per Single Share|Accounting Value of a Share ENTX|HYFT: Net Assets per Single Share|Book Value of One Share abvcpharma.com (ABVC)|Book Value per Share CPIX|Quantum BioPharma Ltd. - Net Assets per Share|FGEN - Net Assets per Single Share|TELO - Net Assets per Single Share|ranitherapeutics.com - Book Value per Share|Synergy CHC (SNYR) - Net Assets per Share|RLYB (Rallybio Corp) - Book Value per Share|Book Value per Share LEXX|Net Assets per Single Share Pulmatrix Corp PULM|Equity per Share ftzy.com.cn PTHL|Accounting Value per Share Aptorum Group|Accounting Value of a Share lyratherapeutics.com LYRA|Book Value per Share IBO (Impact BioMedical Inc)|TNFA: Net Assets per Share|Net Assets per Single Share cbdmd.com|Equity per Share PainReform Corp|Altamira Therapeutics Ltd (CYTO) - Accounting Value per Share|Book Price of a Share lipella.com|OptiNose - Book Value per Share|Net Asset Value per Share PIRS (Pieris Pharmaceuticals Inc)|Net Assets per Single Share Procaps Group SA|Petros Pharma - Accounting Value of a Share|Acelyrin, Inc. (SLRN) - Net Assets per Single Share|TFFP - Equity per Share